CA2470235A1 - Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof - Google Patents
Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof Download PDFInfo
- Publication number
- CA2470235A1 CA2470235A1 CA002470235A CA2470235A CA2470235A1 CA 2470235 A1 CA2470235 A1 CA 2470235A1 CA 002470235 A CA002470235 A CA 002470235A CA 2470235 A CA2470235 A CA 2470235A CA 2470235 A1 CA2470235 A1 CA 2470235A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- patient
- administering
- reducing
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Abstract
The present invention relates to compositions containing unacetylaed ghrelin and derivatives thereof and their uses in the control of glycemia in ageing patients, GH deficient patients, diabetic patients and obese patients.
Claims (57)
1. A composition for preventing and/or reducing postprandial induction of insulin resistance comprising a therapeutically effective amount of at least one of unacylated ghrelin, an analog thereof and a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier.
2. The composition of claim 1, wherein said unacylated ghrelin is having an amino acid as set forth in SEQ ID NO:1.
3. A method for reducing postprandial induction of insulin resistance in a patient comprising the step of administering a therapeutically effective amount of the composition of one of claims 1 and 2 to said patient.
4. The method of claim 3, wherein said administering is through a route selected from the group consisting of intravenous, subcutaneous, transdermal, oral, buccal, sublingual, nasal and by inhalation.
5. The method of claim 3, wherein said administering is in a dose varying from about 0,001 µg/kg to 10,0 µg/kg.
6. The method of claim 3, wherein said administering is in a dose varying from about 1 µg/kg to 1 mg/kg.
7. Use of the composition of one of claims 1 and 2 for reducing postprandial induction of insulin resistance in a patient.
8. Use of the composition of one of claims 1 and 2 for the preparation of a medicament for reducing postprandial induction of insulin resistance in a patient.
9. A composition for preventing and/or reducing dawn phenomenon in type I diabetes patient comprising a therapeutically effective amount of at least one of unacylated ghrelin, an analog thereof and a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier.
10. The composition of claim 9, wherein said unacylated ghrelin is having an amino acid as set forth in SEQ ID NO:1.
11. A method for preventing and/or reducing dawn phenomenon in type I diabetes patient comprising the step of administering a therapeutically effective amount of the composition of one of claims 9 and to said patient.
12. The method of claim 11, wherein said administering is through a route selected from the group consisting of intravenous, subcutaneous, transdermal, oral, buccal, sublingual, nasal and by inhalation.
13. The method of claim 11, wherein said administering is in a dose varying from about 0,001 µg/kg to 10,0 µg/kg.
14. The method of claim 11, wherein said administering is in a dose varying from about 1 µg/kg to 1 mg/kg.
15. Use of the composition of one of claims 9 and 10 for preventing and/or reducing dawn phenomenon in type I diabetes patient.
16. Use of the composition of one of claims 9 and 10 for the preparation of a medicament for preventing and/or reducing dawn phenomenon in type I diabetes patient.
17. A composition for reducing body weight increased in a patient suffering from at least one of type II diabetes and syndrome X comprising a therapeutically effective amount of at least one of unacylated ghrelin, an analog thereof, and a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier.
13. The composition of claim 17, wherein said unacylated ghrelin is having an amino acid as set forth in SEQ ID NO:1.
19. The composition of claim 17, wherein said patient is treated with oral antidiabetic drugs.
20. A method for reducing a body weight increased encountered by a patient suffering from at least one of type II diabetes and syndrome X
comprising the step of administering a therapeutically effective amount of the composition of one of claims 17 to 19.
comprising the step of administering a therapeutically effective amount of the composition of one of claims 17 to 19.
21. The method of claim 20, wherein said administering is through a route selected from the group consisting of intravenous, subcutaneous, transdermal, oral, buccal, sublingual, nasal and by inhalation.
22. The method of claim 20, wherein said administering is in a dose varying from about 0,001 µg/kg to 10,0 µg/kg.
23. The method of claim 20, wherein said administering is in a dose varying from about 1 µg/kg to 1 mg/kg.
24. Use of the composition of one of claims 17 to 19 for reducing a body weight increased encountered by a patient suffering from at least one of type II diabetes and syndrome X.
25. Use of the composition of one of claims 17 to 19 for the preparation of a medicament for reducing a body weight increased encountered by a patient suffering from at least one of type II diabetes and syndrome X.
26. A composition for facilitating treatment of an insulin-resistant patient comprising a therapeutically effective amount of at least one of unacylated ghrelin, an analog thereof and a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier.
27. The composition of claim 26, wherein said unacylated ghrelin is having an amino acid as set forth in SEQ ID No:1.
28. A method for facilitating treatment of insulin-resistant patient comprising the step of administering a therapeutically effective amount of the composition of one of claims 26 and 27 to said patient.
29. The method of claim 28, wherein said administering is through a route selected from the group consisting of intravenous, subcutaneous, transdermal, oral, buccal, sublingual, nasal and by inhalation.
30. The method of claim 28, wherein said administering is in a dose varying from about 0,001 µg/kg to 10,0 µg/kg.
31. The method of claim 28, wherein said administering is in a dose varying from about 1 µg/kg to 1 mg/kg.
32. Use of the composition of one of claims 26 and 27 for facilitating treatment of insulin-resistant patient.
33. Use of the composition of one of claims 26 and 27 for the preparation of a medicament for facilitating treatment of insulin-resistant patient.
34. A composition for decreasing tat mass in a growth hormone-deficient patient comprising a therapeutically effective amount of at least one of unacylated ghrelin, an analog thereof and a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier.
35. The composition of claim 34, wherein said unacylated ghrelin is having an amino acid as set forth in SEQ ID NO:1.
36. A method for decreasing fat mass in a growth hormone-deficient patient comprising the step of administering a therapeutically effective amount of the composition of one of claims 34 and 35 to said patient.
37. The method of claim 36, wherein said administering is through a route selected from the group consisting of intravenous, subcutaneous, transdermal, oral, buccal, sublingual, nasal and by inhalation.
38. The method of claim 36, wherein said administering is in a dose varying from about 0,001 µg/kg to 10,0 µg/kg.
39. The method of claim 36, wherein said administering is in a dose varying from about 1 µg/kg to 1 mg/kg.
40. Use of the composition of one of claims 34 and 35 for decreasing fat mass in a growth hormone-deficient patient.
41. Use of the composition of one of claims 34 and 35 for the preparation of a medicament for decreasing fat mass in a growth hormone-deficient patient.
42. A composition for decreasing fat mass in an ageing patient having a high body mass index comprising a therapeutically effective amount of at least one of unacylated ghrelin, an analog thereof and a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier.
43. The composition of claim 42, wherein said unacylated ghrelin is having an amino acid as set forth in SEQ ID NO:1.
44. A method for decreasing fat mass in an ageing patient having a high body mass index comprising the step of administering a therapeutically effective amount of the composition of one of claims 42 and 43 to said patient.
45. The method of claim 44, wherein said administering is through a route selected from the group consisting of intravenous, subcutaneous, transdermal, oral, buccal, sublingual, nasal and by inhalation.
46. The method of claim 44, wherein said administering is in a dose varying from about 0,001 µg/kg to 10,0 µg/kg.
47. The method of claim 44, wherein said administering is in a dose varying from about 1 µg/kg to 1 mg/kg.
48. Use of the composition of one of claims 42 and 43 for decreasing fat mass in an ageing patient having a high body mass index.
49. Use of the composition of one of claims 42 and 43 for the preparation of a medicament for decreasing fat mass in an ageing patient having a high body mass index.
50. A composition for preventing and/or reducing insulin resistance in a patient comprising a therapeutically effective amount of at least one of unacylated ghrelin, an analog thereof and a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier.
51. The composition of claim 50, wherein said unacylated ghrelin is having an amino acid as set forth in SEQ ID NO:1.
52. A method for preventing and/or reducing insulin resistance in a patient in severe catabolism comprising the step of administering to said patient a therapeutically effective amount of the composition of one of claims 50 and 51.
53. The method of claim 52, wherein said administering is through a route selected from the group consisting of intravenous, subcutaneous, transdermal, oral, buccal, sublingual, nasal and by inhalation.
54. The method of claim 52, wherein said administering is in a dose varying from about 0,001 µg/kg to 10,0 µg/kg.
55. The method of claim 52, wherein said administering is in a dose varying from about 1 µg/kg to 1 mg/kg.
56. ~Use of the composition of one of claims 50 and 51 for preventing and/or reducing insulin resistance in a patient in severe catabolism.
57. ~Use of the composition of one of claims 50 and 51 for the preparation of a medicament for preventing and/or reducing insulin resistance in a patient in severe catabolism.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2470235A CA2470235C (en) | 2001-12-18 | 2002-12-18 | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2365704 | 2001-12-18 | ||
| CA2,365,704 | 2001-12-18 | ||
| PCT/CA2002/001964 WO2003051389A2 (en) | 2001-12-18 | 2002-12-18 | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof |
| CA2470235A CA2470235C (en) | 2001-12-18 | 2002-12-18 | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2470235A1 true CA2470235A1 (en) | 2003-06-26 |
| CA2470235C CA2470235C (en) | 2012-02-07 |
Family
ID=32851583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2470235A Expired - Fee Related CA2470235C (en) | 2001-12-18 | 2002-12-18 | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2470235C (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005039624A1 (en) * | 2003-10-24 | 2005-05-06 | Theratechnologies Inc. | Use of ghrelin and unacylated ghrelin compostions in insulin-related disease conditions |
| US7485620B2 (en) | 2001-12-18 | 2009-02-03 | Alizé Pharma SAS | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof |
| US7666833B2 (en) | 2001-12-18 | 2010-02-23 | Alizé Pharma SAS | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof |
| US8222217B2 (en) | 2007-05-31 | 2012-07-17 | Alize Pharma Sas | Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders |
| US8318664B2 (en) | 2007-05-31 | 2012-11-27 | Alize Pharma Sas | Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity |
| US8476408B2 (en) | 2008-06-13 | 2013-07-02 | Alize Pharma Sas | Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease |
| US9550821B2 (en) | 2011-12-15 | 2017-01-24 | Alize Pharma Sas | Modulation of ghrelin levels and ghrelin/unacylated ghrelin ratio using unacylated ghrelin |
-
2002
- 2002-12-18 CA CA2470235A patent/CA2470235C/en not_active Expired - Fee Related
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7485620B2 (en) | 2001-12-18 | 2009-02-03 | Alizé Pharma SAS | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof |
| US7666833B2 (en) | 2001-12-18 | 2010-02-23 | Alizé Pharma SAS | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof |
| US8071368B2 (en) | 2001-12-18 | 2011-12-06 | Alizé Pharma SAS | Methods for promoting growth and survival of insulin-secreting cells |
| WO2005039624A1 (en) * | 2003-10-24 | 2005-05-06 | Theratechnologies Inc. | Use of ghrelin and unacylated ghrelin compostions in insulin-related disease conditions |
| US7825090B2 (en) | 2003-10-24 | 2010-11-02 | Alizé Pharma SAS | Use of ghrelin and unacylated ghrelin compositions for treating insulin resistance |
| US8222217B2 (en) | 2007-05-31 | 2012-07-17 | Alize Pharma Sas | Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders |
| US8318664B2 (en) | 2007-05-31 | 2012-11-27 | Alize Pharma Sas | Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity |
| US8476408B2 (en) | 2008-06-13 | 2013-07-02 | Alize Pharma Sas | Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease |
| US9550821B2 (en) | 2011-12-15 | 2017-01-24 | Alize Pharma Sas | Modulation of ghrelin levels and ghrelin/unacylated ghrelin ratio using unacylated ghrelin |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2470235C (en) | 2012-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3434687B1 (en) | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same | |
| Raeder et al. | Axillary brachial plexus block with ropivacaine 7.5 mg/ml: A comparative study with bupivacaine 5 mg/ml | |
| JP2005520778A5 (en) | ||
| JP2004504406A5 (en) | ||
| ITRM960790A1 (en) | USE OF SUBSTANCES THAT ACTIVATE THE RECEPTOR OF CNTF (NEUROTRAL FACTOR CILIAR FACTOR) FOR THE PREPARATION OF DRUGS FOR THE THERAPY OF | |
| AU2527800A (en) | Methods to enhance white blood cell count | |
| CA2452872A1 (en) | Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic | |
| CA2729938A1 (en) | New insulin analogues of prolonged activity | |
| EP1526864A2 (en) | Prevention and treatment of nonalcoholic fatty liver disease (nafld) by antagonism of the receptor to glucose-dependent insulinotropic polypeptide (gip) | |
| JP2009519949A5 (en) | ||
| CA2798518A1 (en) | Pegylated c-peptide | |
| RU2013139651A (en) | NEW COMPOUNDS INFLUENCING FOOD BEHAVIOR | |
| IL294521A (en) | Glp-1 compositions and uses thereof | |
| WO1993000083A1 (en) | Pharmaceutical composition containing gamma-hydroxybutyric acid or its lactone in the treatment of drug dependence and nutritional disorders | |
| CA2470235A1 (en) | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof | |
| IL194500A0 (en) | Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application | |
| CA2142455A1 (en) | Method for systemic treatment of catabolic conditions and systemic tissue injury | |
| JP2011522864A5 (en) | ||
| US5491150A (en) | Supplementary therpeutic agents for the treatment of immunodeficiency syndrome | |
| JP2003514025A5 (en) | ||
| CA2543507A1 (en) | Use of ghrelin and unacylated ghrelin compositions in insulin-related disease conditions | |
| JP2002530353A5 (en) | ||
| WO2013003593A1 (en) | Methods of use of hsp70 for increased performance or hsp70 related disorders | |
| AU2019229469A1 (en) | GLP-1 composition for treating obesity and weight management | |
| CA2547873A1 (en) | Tetrapeptide regulating blood glucose level in diabetes mellitus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20201218 |